Background
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It is characterized by a decline of glomerular filtration rate at advanced disease stage and a high inter-and intrafamilial variability in age of end stage renal disease (ESRD) onset, implying a challenge to predict individuals' disease progression. The development and continued accretion of cysts, as the most prominent feature in ADPKD, leads to a massive enlargement of the kidney and, subsequently, to a loss of its function. So far, no disease modifying treatment is available, except the recent approval of the vasopressin V 2 receptor antagonist Tolvaptan in Japan. Due to glomerular hyperfiltration of the remaining nephrons kidney function stays stable over decades. Thus, traditional markers for kidney function like serum creatinine and estimated glomerular filtration rate (eGFR) have limited ability to accurately assess disease state and to predict progression in the early course of ADPKD. Increasing evidence suggests that total kidney volume qualifies as a marker for disease progression in ADPKD [1] . In fact, the disease state may be reflected more accurately by total kidney volume and kidney growth rate than renal functional parameters like eGFR or creatinine clearance [2] . Total kidney volume can be accurately assessed by Magnetic Resonance Imaging (MRI). However MRI derived kidney volume measurements are time and cost intensive, require high technical expertise and are not routine clinical practice.
Renal cystogenesis in ADPKD is a complex process, characterized by abnormalities in tubular cell proliferation, fluid secretion, extracellular matrix formation, and cell polarity [3] . The process results in an impaired filtration barrier, diminished tubular reabsorption, upregulation of tubular proteins and release of markers by recruited inflammatory cells, which can be detected in patients' urine [4] . Such markers should have the property to define the patients' state in a certain disease condition, to predict prognosis, and/or to quantify the effect of a pharmacological approach. Mayeux et al defined type 0 biomarkers (diagnostic biomarkers) reflecting the natural history and correlating with clinical indices and biomarkers of type 1 (predictive biomarkers) capturing the effect of an intervention [5, 6] . Biomarkers of type 0 that reflect tubular damage and have been under investigation in various settings of kidney disease are Neutrophil Gelatinase Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Uromodulin (UMOD), Clara Cell Protein 16 (CC16) and albuminuria [6] . NGAL has been extensively investigated as a biomarker, due to its rapid increase in different settings like acute kidney injury, cardiac surgery, and kidney transplantation [7] [8] [9] [10] [11] . KIM-1 does not occur in human urine under physiological conditions and has been described as progression marker in kidney disease [2] . UMOD, the most abundant protein in human urine, regulates tubular function and shows protective properties against uropathogenic Escherichia coli and nephrolithiasis [12] . Decreasing levels of urinary UMOD have been reported in various settings of chronic kidney disease (CKD), like glomerulonephritis, diabetic nephropathy or tubulointerstitial nephropathy [12] [13] [14] [15] . Urinary CC16 is consistently associated with defective endocytic uptake by the proximal tubule. CC16 levels are increased in patients with diabetic and HIV-induced nephropathy, as well as in renal Fanconi syndrome [16, 17] . There is an unmet need to discover new biomarkers that allow an easy and non-invasive assessment of ADPKD disease state. Here, we investigated the potential properties of the aforementioned markers for assessing disease state by evaluating their association with kidney volume and function in patients at early stage of ADPKD.
Methods

Study Subjects
Subjects of the well-described SUISSE ADPKD cohort were eligible for enrolment [18, 19] . Male and female patients with proven ADPKD diagnosis, examined by kidney ultrasonography, according to Ravine criteria, and a positive family history were eligible when aged between 18 and 40 and presenting with an eGFR greater or equal to 70 ml per min per 1.73m 2 as shown in Table 1 [20] . A proof of a mutation in the PKD1 or PKD2 genes was required for enrolment of patients without family history (sequencing analysis by Athena Diagnostics Inc., Worcester, MA, USA). The study was conducted according to the Declaration of Helsinki and Good Clinical Practice Guidelines and was approved by the local ethical board. All patients provided written informed consent.
Study Procedure
Subjects were invited to the outpatient clinic at the Division of Nephrology (University Hospital Zurich). At study visit the medical history was obtained, including medication and ADPKD related complications. Blood pressure measurement was done in duplicate at each arm after 5 minutes of rest in sitting position using an oscillometric blood pressure device (Boso-Medicus, Jungingen, Germany). Hypertension was defined as systolic blood pressure above 140 mmHg and/or diastolic blood pressure above 90 mmHg or antihypertensive treatment. Fasting spot urine samples were collected after voiding the first urine of the day to measure creatinine beside the potential biomarkers. Blood samples were centrifuged and aliquoted, according to a standardized process, to obtain serum. Serum and spot urine aliquots were stored at-80°C before analysis.
Laboratory Analysis
At study visit, serum creatinine was measured according to modified Jaffé method traceable to an isotope-dilution mass spectroscopy reference. Estimated GFR was calculated by applying 
Magnetic Resonance Imaging
Patients underwent magnetic kidney imaging without contrast media according to a standardized imaging protocol. The imaging was performed using a Signa Excite HDx system (GE Healthcare, Waukesha, WI, USA) and signal perception was obtained with an eight-channel antero-posterior-phased array surface coil. Trans-axial sequences consisted of two breathhold T1-weighted fast-spoiled gradient echo sequences with 3 and 4 mm slice thicknesses. Additionally, a trans-axial T2-weighted fast spin echo sequence with respiratory triggering was performed with 3 mm slice thickness. Right and left kidney volumes were measured and calculated using the Advantage Windows workstation (4.4 GE Healthcare, Buc, France). Total kidney volume (TKV) was calculated by adding the volume of the left and right kidney. Measurements of renal volume were done in a blinded way by two trained and independent observers. The renal hilum and the vessels were excluded from renal volume calculation. Variability was calculated as concordance correlation coefficients (95% CI) and were 1.000 (0.999-1.000) for intraobserver and 0.996 (0.995-0.999) for interobserver correlations [24] .
Statistical Analysis SAS 9.4 was used for data analysis. A plausibility check of the data preceded the statistical analysis. Univariate methods were used to characterize study population. Values are given in means with standard deviation. TKV and height adjusted kidney volume (htTKV) are reported as median because of a skewed distribution of these parameters. Median is reported with interquartile range. Spearman's correlation coefficient (r) was calculated to describe the correlation between biomarkers and eGFR and htTKV. To calculate r, reflecting the relative variance part, all values of the parameters are sorted and given a rank [25] . A positive r indicates a concordant association, whereas a negative r stands for an opposing association.
The association of biomarkers with eGFR and htTKV was evaluated by incorporating different control variables for adjustment and following a multiple linear regression approach. A stratum specific correlation analysis was performed for binary and ordinal variables. Multiple regression analysis gives information about importance and size effect of the predictors on the response variable, and about the interaction between predictors. Prerequisites, like the independence of predictors to each other, were evaluated and fulfilled. The models were determined with scatterplots and correlation analysis to verify linearity between outcome variable and predictors. Subsequently the regression equation was formed. Adjusted R 2 and pvalue were calculated as statistic measures. R 2 , the coefficient of determination, reflects the proportion response variation that is explained by the predictors [26] . Predictor variables were selected according to logical considerations and added sequentially to the models. The models were compared using the Akaike information criterion (AIC). The AIC is based on the likelihood and determines which model is more likely to be correct and comes closer to the "truth" [27] . The smaller the AIC value the more realistic the model is, assuming, that a robust model predicts the data well containing preferably a low number of predictors meeting the requirement for parsimony and avoiding overfitting [28] . Bootstrapping was applied to estimate the 2.5 th and 97.5 th percentile confidence intervals for each model. Our dataset was used as a pool from which 500 new datasets of the same size were randomly drawn with replacement to internally validate our model results.
Results
Demographics
Between Table 2) .
Analysis of biomarker
The results of the urinary parameters osmolality, NGAL, KIM-1, UMOD, UACR and CC16 were tabulated for the complete cohort and stratified for eGFR and TKV ( Correlation of biomarker with indices of disease progression Table 4 shows the correlation of biomarkers with eGFR and TKV. Estimated GFR was negatively correlated with TKV (r = -0.44508, p<0. Regression analysis for htTKV and eGFR as outcome parameter
Simple and multiple linear regression analysis were applied to delineate the independent associations of urinary biomarkers with eGFR and htTKV. Kidney volume is affected by a number of a priori known biological factors, e.g. age, gender, and glomerular filtration rate. Predictive variables were chosen in a predefined step-wise approach: In model 1 (Table 5 ) eGFR (β = -0.45968, p<.0001) was selected as a predictor; the term eGFR captures race, age and gender. The prognostic power of eGFR to predict htTKV is 20.6% (R 2 = 0.2055) with an AIC of -199.6.
Bootstrapping revealed a percentile confidence interval of 0.0987 and 0.3374. (Table 7) . A percentile confidence interval of 0.2866 to 0.5278 was obtained in bootstrap validation. Out of the seven aforementioned variables, eGFR, osmolality, UACR and KIM-1 are major factors to predict htTKV. In model 3, the variable UACR is the second largest predictor variable with a β of 0.30403. Osmolality had a β of 0.21408, and KIM-1 a β of 0.18993. NGAL, UMOD and CC16 had low β-values and were minor determinants in the prognosis of htTKV. In model 3 osmolality, UACR and KIM-1 are positively correlated with kidney volume. The AIC of model 3 was -209.9. The additional selection of KIM-1, NGAL, UMOD and CC16 did not increase R 2 and did not change AIC.
Subsequently different models were established to predict eGFR. In model 1 (Table 8 ) htTKV and osmolality were added on priory knowledge to predict eGFR. Both variables were independently associated with eGFR, and htTKV (β = -0.49803) had a larger association with eGFR compared with osmolality (β = 0.22936). The adjusted R 2 for this model is 0.2515 (percentile CI, 0.1588-0.3809) and thus approximately 25% of eGFR variation is explained by htTKV and osmolality. In model 2 ( Table 9 ) the predicting parameters htTKV, osmolality and UACR account for 22.09% of eGFR variation with an adjusted R 2 of 0.2209. A percentile confidence interval of 0.1319 to 0.3738 was obtained in bootstrap validation. The predictor htTKV has the largest impact on the outcome in this model (β = -0.48736) and osmolality showed the second largest value for standardized estimate (β = 0.21857). UACR has a comparably low β. In model 3 (Table 10 ) the parameters htTKV, osmolality, UACR, NGAL, KIM-1, UMOD and CC16 were entered. Height adjusted total kidney volume (β = -0.47261; p<.0001) and osmolality (β = -0.27024; p = 0.006) were independently associated with changes of eGFR. The 
Discussion
The cystogenesis in ADPKD replaces functional renal parenchyma and leads to a loss of kidney function during patients' lifespan. Since GFR, a traditional parameter of renal function, is not able to accurately assess disease state in the early disease course, the interest in establishing urinary biomarkers for ADPKD has increased. In this cross-sectional study, we investigated the potential biomarkers osmolality, UACR, NGAL, UMOD, CC16, KIM-1 at a single time point in spot urine samples of 139 ADPKD patients with preserved renal function. Robust statistical approach demonstrated that urinary KIM-1, urinary osmolality and UACR are independently associated with kidney volume in our cohort of ADPKD patients. An increase in urinary KIM-1, that is only fractionally expressed under physiological conditions, reflects tubular damage in the proximal S3 tubule segment as shown in acute and chronic kidney injury [29] . In our study, KIM-1 showed the strongest correlation with TKV. Multiple regression analysis revealed an independent correlation of KIM-1 with kidney volume, after adjustment for eGFR, osmolality, UACR, NGAL, UMOD, and CC16. In contrast, KIM-1 was not associated with renal function in multiple regression analysis adjusted for renal volume, osmolality, UACR, NGAL, KIM-1, UMOD, and CC16. KIM-1 expression was found in murine polycystic kidneys but not in wild type mice, driving the hypothesis that ADPKD patients may display higher urinary KIM-1 excretion [29] . KIM-1 has been identified as novel ciliary molecule. By interacting with the PKD2 Protein Transient Receptor Potential Polycystic 2, KIM-1 may be involved in cellular response to changes in extracellular fluid flow detected by the cilium [30] . To our knowledge urinary KIM-1 levels in ADPKD has only been reported once. In a study of Meijer et al increased KIM-1 levels in 24h urine samples of ADPKD patients were associated with total kidney volume, adjusted for age, gender and albuminuria compared with healthy volunteers [2] . In our study, KIM-1 was associated with TKV whereas renal function that is stable at early disease stage was not associated with KIM-1. Given the limited available data of KIM-1 in APDKD patients, it is not possible to draw a conclusion about the property of KIM-1 as biomarker in early ADPKD. A defect in osmoregulation has been shown in animal models of ADPKD as well as in patients [31] [32] [33] . The impaired capacity of urine concentration is an early manifestation and can be observed in children [33, 34] . With our study we confirm the independent association of osmolality and TKV as shown by Ho et al [33] . Following multiple adjustment, urine osmolality is independently associated with kidney volume and function in our cohort. Hence, the assessment of spot urine osmolality may add further information for disease state assessment in ADPKD patients at early disease stage.
Albuminuria is known as marker for kidney damage for years. Urinary albumin excretion is routinely assessed in the diagnosis of renal injury, due its urinary appearance prior to GFR decline in different renal diseases. Albuminuria is associated with CKD progression, decreasing eGFR, increasing TKV, myocardial infarction and mortality [24, [35] [36] [37] [38] [39] . In our study, UACR predicts the variation in htTKV but did not qualify as predictor for kidney function.
KIM-1, urine osmolality and UACR are independently associated with disease state in our study, but no association of NGAL, UMOD and CC16 with kidney volume and function at early ADPKD state was found. NGAL has been extensively studied as biomarker in acute kidney injury, but only limited data is available reporting NGAL levels in ADPKD [7] [8] [9] [10] [11] 40] . Boligano et al reported markedly increased urinary NGAL levels in ADPKD patients at late disease state (eGFR 59 ± 38 ml per minute, Cockcroft-Gault formula) compared with healthy volunteers [41] . Parikh and colleagues investigated serum and urinary NGAL levels over a three year period in participants of the CRISP study, with kidney function comparable to our investigated cohort (creatinine clearance >70 mls/min). The majority of subjects showed normal to low baseline urinary NGAL levels. Even so the levels increased during the study period with a drop at 2 nd and third year follow up, no association of NGAL quartiles with kidney volume and function were seen. Furthermore they showed highly elevated NGAL levels in cystic fluid in ADPKD patients compared to urine and serum values of healthy and of patients with AKI. The discrepancy of NGAL levels in urine and in cyst fluid may be attributable to a missing communication between tubules and detaching cysts in ADPKD [40] . In summary, NGAL levels may increase only in advanced disease and NGAL is not suitable to predict outcome at early stage when renal function is maintained. To our knowledge, UMOD and CC16 levels have not been reported in ADPKD so far. In our study, no association of UMOD and CC16 with renal function and kidney volume was observed. Decreasing levels of urinary UMOD, which is the most abundant protein in human urine, have been reported in various settings of CKD [12] [13] [14] [15] . Since the absolute values for urinary UMOD in our cohort are comparable with the ones reported in various cohorts, one could speculate that UMOD excretion decline starts in later stage of ADPKD [42, 43] . CC16 is secreted by bronchial Clara cells and, after filtration, reabsorbed by receptor-mediated endocytosis in the early segments of the proximal tubule [17] . Hence, all disorders associated with defective proximal tubule endocytosis lead to the urinary loss of CC16 [44] . The described lack of association of CC16 with kidney volume in contrast to KIM-1 probably reflects the functional segmentation of the proximal tubule, with endocytosis being particularly active in the S1-S2 segments whereas secretory pathways take place in the S3 segment [45] .
Our cross-sectional study has to be interpreted in the context of the study setting. We report independent association between biomarkers and outcome of a relatively high number of young ADPKD patients. We are not able to conclude about causal relationships between urinary biomarkers and outcome parameter. The parameters were only investigated at a single time point and we are not able to infer whether or not biomarker excretion precedes decrease in renal function and increase in kidney volume. Furthermore, our results are based on a single centre in the absence of comparative groups of healthy volunteers or other CKD patients, making it impossible to assess the specificity of our findings for ADPKD. To partially account for the study limitations, we performed internal validation of our data set by bootstrapping. Despite adjustment for multiple confounders of our predictive models, we are not able to fully eliminate the potential for bias and confounding. We followed a robust and reliable statistical approach to investigate the diagnostic properties of different urinary biomarkers in a large cohort of ADPKD patients in early disease stage. Based on our results we hypothesize that osmolality, UACR and KIM-1 may have the property to assess disease state at early ADPKD disease course, whereas NGAL, UMOD and CC16 seem not to qualify as biomarkers. Further studies are necessary to define the biomarker properties of the investigated parameter to predict disease burden in ADPKD. 
